Shire prunes Sanfilippo A drug after a failed PhIIb
Shire is knocking one of its rare disease drugs out of the pipeline. SHP610, once cited in Flemming Ornskov’s plan to swell revenue, is being punted after the drug failed a Phase IIb for patients with Sanfilippo A. The therapy missed the primary endpoint on improving cognition.
Shire’s shares $SHPG dropped more than 3% this morning, as analysts looked over a disappointing $386 million loss for Q3, which was worse than the market had reckoned on.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.